Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trialJordana B. Cohen, Julio A. Chirinos, Juan E. Rodriguez‐Mori et al.|The Lancet Respiratory Medicine|2021Cited by 224
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority studyJean‐Michel Molina, Steven L. Chuck, Jaime Andrade‐Villanueva et al.|The Lancet Infectious Diseases|2011Cited by 172
Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial ProtocolJordana B. Cohen, Julio A. Chirinos, Thomas C. Hanff et al.|Journal of Clinical Hypertension|2020Cited by 19